An open-label, uncontrolled phase II trial of HDAC inhibitor LBH589 in patients with chemo-refractory metastatic gastric cancer overexpressing histone deacetylases - CLBH589BDE03T.

Trial Profile

An open-label, uncontrolled phase II trial of HDAC inhibitor LBH589 in patients with chemo-refractory metastatic gastric cancer overexpressing histone deacetylases - CLBH589BDE03T.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2013

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Barrett's oesophagus; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Feb 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 11 Dec 2012 Planned End Date changed from 9 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 07 Feb 2012 Additional lead trial center and investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top